Neoadjuvant therapy for stage II-IVA esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have esophageal squamous cell carcinoma confirmed by biopsy.
- Your age must be between 18 and 75 years.
- Your cancer stage must be II, III, or IVA and considered removable by surgery.
- You cannot have received any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- You must be in good general health with adequate organ function (blood counts, liver, kidney, heart, and lungs).
- You must agree to use effective contraception during treatment and for 3 months afterward, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
Hear when a new PD-1 Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.